GLG News by Lexapro Prescribers: Psychiatrists (US)

1. Pediatric bipolar disorder is an urgent public health problem 2. There is added recognition that this can occur in children 3. Very difficult to diagnose-need comprehensive assessment to ensure accurate diagnosis and as importantly not 'overdiagnosing'

I am a psychiatrist in private practice in a major metropolitan area that has a diverse population. I offer the following observations based on my clinical post-marketing experience. I have already prescribed Vyvanse to a few hundred patients. My observations: 1. Duration of action: This is a huge issue....

1. This agent despite a favorable side effect profile lacks efficacy as compared to other antipsychotic agents already approved by the FDA. 2. This is a temporary setback for Wyeth. 3. This in the long run is to Wyeth's advantage as such an agent would have done poorly in a competitive atypical antipsychotic...

Dov pharmaceuticals has a new triple reuptake inhibitor (serotonin, norepinephrine, and dopamine) in early trials and it sounds promising but with some serious reservations.

The FDA advisory regarding caution in prescribing antidepressants to the pediatric population has had adverse effects potentially lethal to patients in need. 

1. Most currently marketed oral antidepressants replenish only norepinephrine or serotonin and result in remission in less than 45% of patients over 8 weeks. A triple reuptake inhibitor such as DOV 21,947 has the potential to effect a remission in a higher percentage of patients. 2. Most of the...

1. An antipsychotic with a novel mechanism of action is highly desirable as currently available atypical antipsychotic agents lack efficacy or cause undesirable side effects (metabolic, extrapyramidal, increased prolactin.) 2. If this agent demonstrated significant efficacy and safety it could be a...

1. BL-1020 represents an important advance from Israel's top drug development company 2. Unique mechanism without Parkinsonian side effects or cardiovascular, metabolic, weight gain (from atypical antipsychotics 3. This may enhance treatment adherence with better outcomes 4. Likely will be useful...

1) Because of its excellent safety profile, enhanced side effect profile (e.g, weight gain, carbohydrate metabolism abnormalities) compared to other atypical antipsychotics such as risperdol, zyprexa and seroquel, this is an exciting 'go-to' medication 2) Best for augmentation, and one of our go-to...

Sepracor is reaching out to other continents in an attempt to expand its profitability related to Lunesta.  How this plays out in the long run must take into account another sleeper, Indiplon, from Neurocrine Biosciences(NBIX), which will be up for approval probably by the end of the year.